Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.
Advanced Solid Tumors
DRUG: SPH4336 Tablets
Maximum tolerated dose（MTD）, Measurement of MTD of SPH4336 in all subjects, Up to 28 days|Dose-limiting toxicity (DLT), Measurement of DLT of SPH4336 in all subjects, Up to 28 days
Objective response rate (ORR), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1., Up to 1 year|Progression-free survival (PFS), From the start date of study treatment to the date of progression disease or death , whichever occurred first., Up to 1 year|Cmax, PK (Pharmacokinetics) parameters, predose,1,2,4,5,6,8,10,12,24 hours post-dose|Tmax, PK (Pharmacokinetics) parameters, predose,1,2,4,5,6,8,10,12,24 hours post-dose|Disease control rate (DCR), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease., Up to 1 year|Duration of remission (DOR), DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response to the date of disease progression per RECIST v1.1 or death from any cause., Up to 1 year|Safety and tolerability, Adverse event type, incidence, duration, correlation with study drug., Up to 1 year
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.